MWAM
CRSP icon

Manhattan West Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Manhattan West Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$499K Sell
9,156
-346
-4% -$18.2K 0.08% 117
2026
Q1 		$452K Buy
9,502
+1,051
+12% +$55.4K 0.09% 109
2025
Q4 		$443K Buy
8,451
+1,310
+18% +$78.5K 0.09% 107
2025
Q3 		$463K Buy
7,141
+298
+4% +$17.1K 0.1% 110
2025
Q2 		$333K Buy
+6,843
New +$265K 0.08% 111
2024
Q1 		– Sell
-3,442
Closed -$215K – 150
2023
Q4 		$215K Buy
+3,442
New +$190K 0.06% 130

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Manhattan West Asset Management's CRSP Position: Q2 2026 in Review

Manhattan West Asset Management reduced its CRISPR Therapeutics (CRSP) stake by 3.6% in Q2 2026, selling an estimated $18.2K and leaving 9,156 shares worth $499K. The position accounts for 0.08% of the portfolio, ranked #117.

Manhattan West Asset Management first reported a position in CRSP in Q4 2023 and has held it in 6 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Manhattan West Asset Management held 9,156 shares of CRISPR Therapeutics worth $499K as of Q2 2026.
  • Manhattan West Asset Management sold 346 CRISPR Therapeutics shares in Q2 2026, an estimated $18.2K.
  • CRISPR Therapeutics made up 0.08% of Manhattan West Asset Management's portfolio in Q2 2026, its #117 holding.
  • Manhattan West Asset Management first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 6 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Manhattan West Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.